Related Experiment Videos
Optimal two-stage designs for phase II clinical trials
1Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892.
Abstract:
The primary objective of a phase II clinical trial of a new drug or regimen is to determine whether it has sufficient biological activity against the disease under study to warrant more extensive development. Such trials are often conducted in a multi-institution setting where designs of more than two stages are difficult to manage. This paper presents two-stage designs that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraints upon the size of the type 1 and type 2 errors. Two-stage designs which minimize the maximum sample size are also determined. Optimum and "minimax" designs for a range of design parameters are tabulated. These designs can also be used for pilot studies of new regimens where toxicity is the endpoint of interest.
Insights
This study introduces optimal two-stage clinical trial designs for phase II drug development. These designs minimize sample size while controlling error rates, ensuring efficient evaluation of new therapies.
Area of Science:
- Clinical Trials
- Biostatistics
- Pharmacology
Background:
- Phase II clinical trials aim to assess drug efficacy for further development.
- Multi-institutional trials require manageable designs, often limiting complex multi-stage approaches.
- Evaluating new drug regimens necessitates robust statistical methodologies.
Purpose of the Study:
- To present optimal two-stage clinical trial designs for phase II studies.
- To minimize expected sample size under low drug activity, subject to Type I and Type II error constraints.
- To determine designs that minimize the maximum sample size (minimax designs).
Main Methods:
- Development of two-stage clinical trial designs.
- Optimization criteria: minimizing expected sample size and maximum sample size.
- Tabulation of optimal and minimax designs for various parameters.
- Application to pilot studies with toxicity endpoints.
Main Results:
- Tabulated optimal two-stage designs that minimize expected sample size.
- Tabulated minimax two-stage designs that minimize maximum sample size.
- Designs are presented for a range of statistical parameters.
Conclusions:
- The presented two-stage designs offer efficient methods for phase II clinical trials.
- These designs are suitable for multi-institutional settings and pilot studies.
- The methodology provides a framework for optimizing sample size and controlling errors in early drug development.